Thymosin Alpha-1 (Tα1) is a 28 amino-acid acetylated peptide isolated from thymus tissue and synthesised since the late 1970s. It is one of the most clinically studied immunomodulatory peptides — used as Zadaxin in over thirty countries for adjunctive treatment of chronic hepatitis B and certain cancers. This article maps the research literature on mechanism and immune modulation.
Origin and sequence
Tα1 is N-acetylated at the alpha-amino group of the N-terminal serine. The full sequence: N-acetyl-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn. The acetylation enhances enzymatic stability.
Mechanism — TLR engagement
The most-cited mechanistic finding is that Tα1 activates Toll-like receptor 9 (TLR9) on plasmacytoid dendritic cells and other antigen-presenting cells. TLR9 activation triggers a type I interferon response, which then cascades into:
- Enhanced dendritic cell maturation and antigen presentation
- Increased Th1 cytokine production (IL-2, IFN-γ)
- Improved natural killer cell activity
- Modulated T regulatory cell function
Chronic hepatitis B research
The largest body of clinical research on Tα1 is in chronic hepatitis B. Meta-analyses of randomised controlled trials (Yang et al., 2008) report improved seroconversion rates and reduced viral load when Tα1 is added to standard antiviral therapy. The effect is modest but reproducible across multiple cohorts.
Cancer adjunct research
Tα1 has been studied as an immune adjunct in hepatocellular carcinoma, malignant melanoma, and non-small-cell lung cancer. The research signal is most consistent in hepatocellular carcinoma post-resection (Zhang et al., 2012), where adjunct Tα1 reduced recurrence rates in research cohorts.
Sepsis research
The ETASS trial (Wu et al., 2013) examined Tα1 in severe sepsis. Results were mixed — primary mortality endpoint was not met, but subgroup analyses suggested benefit in immunosuppressed sepsis phenotypes. Subsequent trials have continued to explore this niche.
COVID-19 research period
During the COVID-19 pandemic, multiple research groups (particularly in Italy and China) examined Tα1 as an immunomodulatory adjunct. The published cohorts were small, but signals included improved lymphocyte counts and reduced mortality in some subgroups. This research is still being aggregated.
Innate vs adaptive immune effects
| Immune arm | Tα1 effect in research |
|---|---|
| Innate | Increased NK cell activity, dendritic cell maturation |
| Adaptive (cellular) | Th1 shift, increased CD4+ and CD8+ proliferation |
| Adaptive (humoral) | Modest antibody response enhancement |
| Regulatory | Treg modulation in autoimmune research models |
Pharmacokinetic profile
- Plasma half-life: ~2 hours after subcutaneous administration
- Excretion: primarily renal
- Standard research dosing: 1.6 mg subcutaneous twice weekly
Stability and reconstitution
Tα1 is supplied lyophilised. Reconstitution in bacteriostatic water at 1–2 mg/mL is standard. Refrigerated reconstituted Tα1 retains potency for approximately 4 weeks. The N-terminal acetylation provides protection against aminopeptidase degradation.
Where the research is heading
- Combination with immune checkpoint inhibitors in oncology research
- Mechanism studies on TLR9 pathway specifics
- Sepsis subgroup identification (which patients respond)
- Vaccine adjuvant research
Chempeptides supplies HPLC-verified Thymosin Alpha-1 with batch CoA — see the catalogue.
Research use only.